Researchers in the Netherlands have developed 3D-printed 'mini tumours' that behave like real cancerous tissue and can be used to test new treatments, including drug and cell-based immunoth
Bayer has advanced its small-molecule drug BAY 2927088 into phase 3 for non-small cell lung cancer (NSCLC) with HER2 activating mutations, one of the drugs central to the company’s plan to
MSD has kicked off a new phase 3 trial of its oral LSD1 inhibitor bomedemstat in essential thrombocythaemia (ET), one of a rare type of blood cancer known as myeloproliferative neoplasms (M
Regeneron's CD20xCD3 bispecific antibody for non-Hodgin lymphoma (NHL) has been approved in Europe, five months after it was turned down by the FDA in the US.
Johnson & Johnson's Balversa has become the first drug approved in the EU to treat adults with advanced urothelial carcinoma (mUC) with FGFR3 genetic alterations after one line of prior
Danish biotech Adcendo has accelerated its progression to a clinical-stage biotech by licensing an antibody-drug conjugate (ADC) from China's Multitude Therapeutics with potential in variou